Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $349,301.40 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $29.40, for a total value of $349,301.40. Following the completion of the transaction, the chief operating officer directly owned 377,802 shares of the company’s stock, valued at approximately $11,107,378.80. The trade was a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

  • On Friday, November 13th, Julie Rubinstein sold 11,466 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.93, for a total value of $331,711.38.
  • On Monday, November 9th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $30.12, for a total value of $357,855.72.
  • On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.53, for a total value of $315,202.93.
  • On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.73, for a total value of $317,579.13.
  • On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total value of $302,609.07.
  • On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total value of $338,014.45.
  • On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
  • On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total value of $296,787.38.
  • On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total transaction of $285,738.05.
  • On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total transaction of $301,896.21.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $29.04 on Monday. The company has a debt-to-equity ratio of 1.82, a quick ratio of 3.87 and a current ratio of 3.97. Adaptive Biotechnologies Corporation has a twelve month low of $12.00 and a twelve month high of $32.21. The firm’s 50 day moving average price is $26.91 and its two-hundred day moving average price is $20.13. The firm has a market cap of $4.70 billion, a P/E ratio of -64.53 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.95%. The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $71.57 million. During the same quarter in the prior year, the company earned $0.06 earnings per share. The business’s quarterly revenue was down 10.7% compared to the same quarter last year. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $324,735,000. Wellington Management Group LLP lifted its stake in Adaptive Biotechnologies by 53.2% in the 2nd quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after purchasing an additional 2,053,944 shares during the last quarter. Bank of America Corp DE acquired a new stake in Adaptive Biotechnologies in the 2nd quarter valued at about $37,109,000. Principal Financial Group Inc. grew its holdings in Adaptive Biotechnologies by 9.8% during the first quarter. Principal Financial Group Inc. now owns 1,704,887 shares of the company’s stock worth $23,664,000 after purchasing an additional 152,378 shares during the period. Finally, First Trust Advisors LP grew its holdings in Adaptive Biotechnologies by 90.8% during the third quarter. First Trust Advisors LP now owns 797,309 shares of the company’s stock worth $23,042,000 after purchasing an additional 379,486 shares during the period. Institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ADPT. National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Guggenheim lifted their price target on Adaptive Biotechnologies from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a research note on Tuesday, September 29th. They issued a “buy” rating and a $35.00 price target on the stock. Morgan Stanley boosted their price target on Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. Finally, BTIG Research upped their price objective on Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.31.

Read Our Latest Analysis on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.

Recommended Stories

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.